China Pharma Holdings, Inc. CPHI PHARMA

Q: What is the current share price of China Pharma Holdings, Inc. (CPHI)?

As of 2026-09-19 21:16 PDT, China Pharma Holdings, Inc. (CPHI) trades at $0.84 on NYSE American. Its 52-week range is $0.52 to $8.10.

Q: What is the market capitalisation of CPHI?

China Pharma Holdings, Inc. (CPHI) has a market capitalisation of $36.14M on NYSE American.

Q: What is the P/E ratio of CPHI?

CPHI trades at a trailing price-to-earnings (P/E) ratio of -2.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.87.

Q: What is the return on equity (ROE) of CPHI?

CPHI has a return on equity (ROE) of -20.99%. Its return on capital employed (ROCE) is -13.73%.

Q: Is CPHI a good stock to buy?

This page provides a data-driven analysis of China Pharma Holdings, Inc. (CPHI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · China

https://www.chinapharmaholdings.com

Company Profile ↓

$0.84

-43.18% 1Y

Mkt Cap$36.14M

P/E-2.00

P/B0.87

52W High$8.10

52W Low$0.52

Book Value$0.89

EPS (TTM)$-0.42

Company Overview

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.11.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $4.14M (-8.5% YoY); net profit $-3.19M.
Trailing 12 Months Year-on-year growth — revenue -7.5%.
5-Year Trend Long-term compounding — revenue CAGR -17.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-17.51%
1 Year:	-7.50%

Stock Price Performance

1 Year:	-43.18%
6 Months:	+40.17%
3 Months:	+18.45%
1 Month:	-25.58%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 4% of range

$0.52 $8.10

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)44.71 · Neutral

Price Performance

1M-25.58%

3M+18.45%

6M+40.17%

1Y-43.18%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -17.5% CAGR over 5 years.
Trading 89.6% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-2.00

Industry PE

24.83

Forward P/E

PEG Ratio

0.16

Book Value

$0.89

Price to Book

0.87

P/S

8.56

EV/EBITDA

-27.72

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-17.51%

Profit 5Y

Revenue (YoY)

-7.50%

Earnings (YoY)

Profitability & Returns

ROCE

-13.73%

ROE

-20.99%

ROA

-9.35%

Profit Margin

Op Margin

Gross Margin

11.76%

EPS (Latest Qtr)

$-0.04

EPS (TTM)

$-0.42

Balance Sheet & Liquidity

Debt/Equity

0.11

Quick Ratio

0.07

Current Ratio

0.26

Debt

$4.06M

Total Assets

$45.14M

Current Assets

Working Capital

Ownership

Promoter Holding

89.63%

Chg in Prom Hold

FII / Inst Holding

0.47%

Chg in FII Hold

0.39%

Financial Snapshot

Enterprise Value

$36.14M

Total Revenue (TTM)

$3.91M

EBITDA

$-1.44M

Free Cash Flow

$1.11M

Operating Cash Flow

$-140.49K

Shares Outstanding

43.02M

Gross Margin

11.76%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CPHI China Pharma Holdings, Inc. PHARMA	0.84	-2.00	$36.14M	0.00%	-13.73%	-20.99%	-17.51%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2013	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	8.25M	8.03M	8.12M	7.11M	6.13M	5.57M	5.69M	5.67M	4.48M	3.64M	3.54M	3.13M	3.29M	2.92M	3.16M	3.62M	3.17M	2.30M	2.93M	2.57M	2.38M	1.76M	3.77M	2.40M	2.36M	2.42M	1.98M	1.60M	1.61M	1.97M	1.96M	1.10M	1.80M	1.37M	924.94K	1.10M	1.14M	1.03M	756.22K	983.54K
Gross Profit	-1.57M	2.15M	2.24M	2.66M	2.42M	1.51M	1.06M	-55.83K	322.00K	640.82K	482.10K	349.97K	717.85K	648.36K	421.54K	1.05M	579.48K	512.54K	656.53K	163.55K	372.76K	194.44K	1.15M	47.20K	272.73K	71.00K	-296.40K	-169.46K	-229.38K	-137.76K	177.92K	-146.66K	-233.19K	-290.02K	-1.02M	-519.65K	-136.06K	-87.01K	-59.65K	285.49K
Operating Income	-3.00M	-4.76M	-2.69M	-2.34M	-8.53M	-5.99M	-3.76M	1.44M	3.19M	-1.32M	-2.22M	-1.55M	-802.63K	-2.13M	-2.06M	-140.69K	-864.40K	-1.93M	-334.21K	-752.97K	-645.20K	-599.28K	74.98K	-952.49K	-696.47K	-752.95K	-762.40K	-911.72K	-779.59K	-688.65K	-397.48K	-456.31K	-713.54K	-916.05K	-1.39M	-1.09M	-758.62K	-652.12K	-628.14K	-1.12M
Net Income	286.84K	-	-	-2.39M	-8.64M	-6.33M	-4.07M	1.13M	2.93M	-1.55M	-2.45M	-1.75M	-966.90K	-2.29M	-2.20M	-293.48K	-1.01M	-1.86M	-417.73K	-838.10K	-700.95K	-660.90K	13.05K	-1.01M	-767.33K	-824.76K	-826.67K	-1.03M	-888.39K	-790.77K	-475.98K	-593.03K	-777.60K	-955.89K	-1.44M	-1.12M	-785.57K	-528.37K	-651.48K	-1.14M
Diluted EPS	-0.06	-0.10	-0.05	-0.05	-0.20	-0.15	-0.09	0.03	0.07	-0.04	-0.06	-0.04	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.02	-0.02	-0.22	-0.18	-0.16	-0.06	-0.35	-0.29	-0.72	-0.89	-0.65	-0.24	-0.16	-0.17	-0.04
R&D Expense	-	-	-	444.41K	1.90M	181.80K	160.83K	174.85K	405.44K	93.43K	96.66K	99.09K	26.06K	21.45K	27.54K	22.21K	23.67K	62.06K	69.92K	66.01K	39.72K	48.82K	30.04K	37.63K	190.09K	53.46K	21.37K	54.05K	15.06K	88.75K	23.01K	23.75K	45.77K	31.45K	164.33K	87.61K	29.59K	20.95K	40.32K	83.76K

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	74.39M	81.17M	54.51M	32.81M	22.13M	20.35M	15.57M	13.21M	12.33M	10.92M	10.87M	9.64M	8.10M	7.01M	4.53M	4.14M
Gross Profit	30.28M	28.99M	14.08M	-480.92K	2.67M	1.46M	3.22M	2.47M	1.97M	1.48M	1.95M	349.27K	-493.92K	-281.08K	-1.99M	-131.95K
Operating Income	24.66M	22.03M	5.91M	-18.61M	-38.76M	-14.30M	-8.16M	-18.68M	-10.45M	-20.41M	-2.58M	-2.86M	-3.55M	-2.75M	-4.59M	-3.24M
Net Income	23.41M	19.27M	4.62M	-20.01M	-39.55M	-15.41M	-9.18M	-19.28M	-10.75M	-20.70M	-2.87M	-3.40M	-3.97M	-3.08M	-4.74M	-3.19M
Diluted EPS	0.54	0.44	0.11	-0.46	-0.91	-0.35	-	-	-	-	-	-0.74	-3.78	-0.91	-2.71	-0.74
R&D Expense	-	-	438.66K	1.68M	2.80M	961.90K	365.97K	90.47K	172.38K	229.64K	377.96K	318.96K	185.86K	240.08K	283.94K	280.90K

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	131.75M	156.39M	163.24M	157.61M	121.08M	96.51M	78.52M	59.95M	45.38M	22.24M	21.12M	22.65M	17.78M	16.47M	14.89M	31.00M
Total Equity	87.87M	117.94M	142.48M	148.52M	132.94M	92.74M	72.64M	58.91M	43.07M	30.20M	9.24M	8.00M	6.02M	4.29M	7.45M	7.75M	22.74M
Cash & Equivalents	3.63M	3.69M	4.05M	4.03M	-	-	6.25M	2.67M	2.03M	1.19M	1.07M	957.65K	4.86M	2.03M	1.42M	626.88K	345.11K
Long Term Debt	-	-	-	-	-	-	-	-	9.22M	6.54M	4.30M	5.24M	-	-	-	-	-
Total Liabilities	-	13.81M	13.91M	14.72M	24.67M	28.34M	23.87M	19.61M	16.88M	15.18M	13.00M	13.11M	16.63M	13.49M	9.01M	7.14M	8.26M
Current Liabilities	-	12.81M	13.78M	14.63M	12.01M	14.17M	12.79M	10.40M	9.23M	10.05M	10.05M	11.40M	10.51M	12.74M	6.82M	5.02M	7.40M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	7.79M	5.24M	3.64M	8.60M	6.15M	3.35M	2.90M	841.22K	1.88M	608.31K	-42.26K	-249.84K	-409.55K	-699.69K	-406.06K	148.26K
Investing Cash Flow	-10.52M	-5.63M	-4.99M	-19.09M	-7.42M	-1.90M	-193.40K	-136.48K	-51.15K	-136.00K	-867.31K	-438.06K	-401.96K	-11.52K	-291.72K	-137.25K
Financing Cash Flow	2.66M	595.67K	1.29M	12.32M	605.00K	0	-6.02M	-1.48M	-1.98M	-1.73M	624.18K	4.60M	-1.77M	73.14K	-33.78K	-294.03K
Capital Expenditure	63.85K	352.36K	156.88K	18.79M	-5.13M	685.30K	-193.40K	-136.48K	-51.15K	-136.00K	-867.31K	-438.06K	-401.96K	-11.52K	-38.41K	-59.32K
Free Cash Flow	7.85M	5.59M	3.80M	27.39M	1.02M	4.04M	2.70M	704.74K	1.83M	472.31K	-909.57K	-687.89K	-811.51K	-711.20K	-444.47K	88.94K

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	40.7%	35.7%	25.8%	-1.5%	12.1%	7.2%	20.7%	18.7%	16.0%	13.6%	18.0%	3.6%	-6.1%	-4.0%	-43.8%	-3.2%
Operating Margin %	33.2%	27.1%	10.8%	-56.7%	-175.1%	-70.3%	-52.4%	-141.4%	-84.7%	-186.8%	-23.7%	-29.7%	-43.8%	-39.2%	-101.3%	-78.2%
Net Margin %	31.5%	23.7%	8.5%	-61.0%	-178.7%	-75.7%	-59.0%	-145.9%	-87.2%	-189.5%	-26.4%	-35.3%	-49.0%	-43.9%	-104.6%	-76.9%
ROE %	19.9%	13.5%	3.1%	-15.0%	-42.6%	-21.2%	-15.6%	-44.8%	-35.6%	-224.1%	-35.8%	-56.5%	-92.6%	-41.3%	-61.1%	-14.0%
ROCE %	20.7%	15.4%	4.0%	-12.8%	-36.3%	-17.1%	-12.0%	-36.8%	-29.6%	-167.4%	-26.5%	-23.6%	-70.4%	-28.5%	-46.5%	-13.7%

Shareholding Pattern

Insiders

89.63%

Institutions

0.47%

Public Float

4.57%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Citadel Advisors Llc	0.29%	125.44K	$89.06K
2	Two Sigma Securities, LLC	0.08%	35.67K	$25.32K
3	Renaissance Technologies, LLC	0.03%	15.04K	$10.68K
4	Jane Street Group, LLC	0.03%	13.89K	$9.86K
5	Ground Swell Capital, LLC	0.02%	10.61K	$7.53K
6	UBS Group AG	0.01%	3.11K	$2.21K
7	Danske Bank A/s	-	1	$0
8	EFG International AG	-	40	$28

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CPHI

Google News Wed, 15 Jul 2026

NYSE American Contacts China Pharma Over Unusual Stock Activity - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNYmp3SEM1eVJXb0kzY1JDeHlKTGRBd2NVQ1dRdUdHNXZ1WGJtc0hPYXpnZ0NhZy15X1FqRUVYSk5SbVpEeGQwVG1adEpjaHFBR3RtVzlDc0k3dXBZSGtXNWFaVk5oZ1NXN3U0eDhSQjlhZUNWQWNZVE81ZkloczVzbUN0bWFTWXBmZjUtbG…

Google News hu, 23 Jul 2026

CPHI Stock Surge: Why China Pharma Rallied 790% Without News - TOP1markets

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQUldOZ1k4RVRkSFJPVHlZazlQWUdnX3AzcjZhaUdIWlpKeGItVEVsNFJRbmtFamJkQ2wzWVd3aGZqNmdXU0NiS0U0dGw1QkZXdEY1NzUyVjdWb1B5ajdwbWwzVFpaXzFlTXo0VXFuOXJhbkZOdG9Ia1Rzc1dqNHJQb3VDVQ?oc=5" targe…

Google News hu, 13 Aug 2026

CPHI Stock Craters As $5M Offering Fuels Extreme Volatility - timothysykes.com

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQcC0zbE1wOEhuS0hGM1ZuWWV6SFFPcGMzRU8tNTBfV0V5dDZfTWVhUlFmTHpMd1IyQk16V3lZZ0xrV0dndFVEbmY2QU51UU1VRE9uWFhIRnRtc2dBdXo2XzNFRUR3SVNiam0weEVRcUlNSTE0QTFqeXg1ZTFCOENYclk3UQ?oc=5" targe…

Google News Wed, 22 Jul 2026

CPHI Stock Whipsaws As Company Denies Hidden News - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxON2QxakQ3YlpOMHJhcVBidmFLdXRYcGxja19SYm40RmJDejdYVEpCMnFnZnJwcThlVVdIOF9yQTNZaGx2YTlRc3lINDRrLVI4enBkVU1aV0FndktvOElYUV9iaWZpWFg1ZW1DcjNXQXpCYlcxUXhOY2pPWkl5TlVzYVg0NFY?oc=5" targ…

Google News ue, 26 May 2026

CPHI - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4wejRPb0R5Nmg2WWlhMU1XS09TSEhBbEZKaUdZRzZFSlp3bnN5VV81blZiRDBseDdLOUI1dHpjNGpfTllMMVE?oc=5" target="_blank">CPHI</a>  <font color="#6f6f6f">Finviz</font>…

Google News Wed, 15 Jul 2026

These stocks are moving in today's after hours session - ChartMill

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZzJQZHF5ZDR6RGlTejY5YUVPMmxNeUsyZ081NzBLaTBLOENrajUwd0I2a1d6SGJLZWZnMnpuN0dqM3JKVF9KVHRGQ05DRWV1czU1dGdIQXJyLUdXcU4zcHgycWRJN2xHMDFMMElhcEVmYW5oZjV4S2dXTkpDN3dHVEYycHkxOW0yektNQU…

CPHI — Frequently Asked Questions

What is the current share price of China Pharma Holdings, Inc. (CPHI)?

As of 2026-09-19 21:16 PDT, China Pharma Holdings, Inc. (CPHI) trades at $0.84 on NYSE American. Its 52-week range is $0.52 to $8.10.

What is the market capitalisation of CPHI?

China Pharma Holdings, Inc. (CPHI) has a market capitalisation of $36.14M on NYSE American.

What is the P/E ratio of CPHI?

CPHI trades at a trailing price-to-earnings (P/E) ratio of -2.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.87.

What is the return on equity (ROE) of CPHI?

CPHI has a return on equity (ROE) of -20.99%. Its return on capital employed (ROCE) is -13.73%.

Is CPHI a good stock to buy?

This page provides a data-driven analysis of China Pharma Holdings, Inc. (CPHI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

China Pharma Holdings, Inc. CPHI PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

NYSE American Contacts China Pharma Over Unusual Stock Activity - Stock Titan

CPHI Stock Surge: Why China Pharma Rallied 790% Without News - TOP1markets

CPHI Stock Craters As $5M Offering Fuels Extreme Volatility - timothysykes.com

CPHI Stock Whipsaws As Company Denies Hidden News - StocksToTrade

CPHI - Finviz

These stocks are moving in today's after hours session - ChartMill

CPHI — Frequently Asked Questions

What is the current share price of China Pharma Holdings, Inc. (CPHI)?

What is the market capitalisation of CPHI?

What is the P/E ratio of CPHI?

What is the return on equity (ROE) of CPHI?

Is CPHI a good stock to buy?

Explore More